A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Safety assessment of bone marrow derived MSC grown in platelet-rich plasma
2015
Regenerative Therapy
The injection of endothelial progenitor cells and mononuclear cells derived from bone marrow at the ischemic region of peripheral artery disease patients is reported to be effective for therapeutic angiogenesis; however, these cell therapies require large amounts of bone marrow to obtain sufficient numbers of cells. To solve this problem, we attempted to culture bone-marrow-derived mesenchymal stem cells (BM-MSC), which are supposed to secrete several cytokines that promote angiogenesis. We
doi:10.1016/j.reth.2015.02.001
pmid:31245443
pmcid:PMC6581768
fatcat:p7q7p3jf6vedhots4ds35kotca